Log in

NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

$17.12
-1.19 (-6.50 %)
(As of 03/29/2020 04:49 AM ET)
Today's Range
$16.60
Now: $17.12
$18.67
50-Day Range
$13.37
MA: $18.95
$22.25
52-Week Range
$10.70
Now: $17.12
$27.68
Volume827,375 shs
Average Volume895,473 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Read More
Dicerna Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.90 million
Book Value$2.22 per share

Profitability

Net Income$-120,460,000.00
Net Margins-503.93%

Miscellaneous

Employees78
Market Cap$1.26 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.


Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

How has Dicerna Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DRNA stock has increased by 1.4% and is now trading at $17.12. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Dicerna Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.50. The biopharmaceutical company earned $7.08 million during the quarter, compared to analysts' expectations of $26.40 million. Dicerna Pharmaceuticals had a negative net margin of 503.93% and a negative return on equity of 76.93%. View Dicerna Pharmaceuticals' earnings history.

What price target have analysts set for DRNA?

10 brokerages have issued 12 month price targets for Dicerna Pharmaceuticals' stock. Their forecasts range from $18.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $31.22 in the next twelve months. This suggests a possible upside of 82.4% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

News stories about DRNA stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutDicerna Pharmaceuticals.

Are investors shorting Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals saw a drop in short interest in February. As of February 28th, there was short interest totaling 3,060,000 shares, a drop of 10.5% from the February 13th total of 3,420,000 shares. Based on an average trading volume of 664,300 shares, the short-interest ratio is currently 4.6 days. Approximately 6.8% of the company's shares are short sold. View Dicerna Pharmaceuticals' Current Options Chain.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), Amarin (AMRN), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Array Biopharma (ARRY), Crispr Therapeutics (CRSP), Exelixis (EXEL) and Gilead Sciences (GILD).

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (5.96%), EcoR1 Capital LLC (5.30%), UBS Group AG (3.20%), Bridger Management LLC (2.90%), Eagle Asset Management Inc. (2.57%) and State Street Corp (2.42%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View institutional ownership trends for Dicerna Pharmaceuticals.

Which major investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, Bridger Management LLC, EcoR1 Capital LLC, UBS Group AG, Sofinnova Investments Inc., Emerald Advisers LLC, State Street Corp, and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, and Peter Kolchinsky. View insider buying and selling activity for Dicerna Pharmaceuticals.

Which major investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Driehaus Capital Management LLC, Marshall Wace LLP, Renaissance Technologies LLC, Parkman Healthcare Partners LLC, Marshall Wace North America L.P., Connor Clark & Lunn Investment Management Ltd., and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Dicerna Pharmaceuticals.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $17.12.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $1.26 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe. View additional information about Dicerna Pharmaceuticals.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  411 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  687
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel